Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design - Hagens Berman
NVO Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - January 31, 2025) - Novo Nordisk A/S (NYSE: ...
optometryadvisor30m
FDA Approves Ozempic to Protect Kidneys in Patients With Type 2 Diabetes
A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans at risk for kidney failure.